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Stress urinary incontinence is a prevalent condition in women with a signiﬁcant negative eﬀect on quality of life. Intervention
includesbehavioralmodiﬁcation,intravaginaldevices,pelvicﬂoormuscleexercises,biofeedback,functionalelectricalstimulation,
and surgical procedures. We will review a new in-oﬃce procedure for the treatment of SUI that may serve as a viable nonsurgical
option.
1.Introduction
Stress urinary incontinence (SUI) is estimated to aﬀect
up to 35% of adult women worldwide [1] and 15.7% of
community-dwelling women domestically [2]. According to
the National Hospital Discharge Survey, there are approx-
imately 100,000 inpatient procedures performed for SUI
in the United States annually, with outpatient procedures
estimated to exceed 105,000 as per the 2006 National Survey
of Ambulatory Surgery [3].
The International Continence Society deﬁnes SUI as “the
complaint of involuntary leakage of urine upon eﬀort or
exertion, or on sneezing or coughing” [4]. In a European
sample of 1573 women with urinary incontinence, >80%
consideredtheirsymptomstobebothersome,withanegative
impact on quality of life as per the Incontinence Quality of
Life Questionnaire (I-QOL) [5]. Risk factors for SUI include,
but are not limited to, age, parity, history of hysterectomy,
forceps delivery, and obesity.
Non-surgical treatment options include behavioral mod-
iﬁcation, intravaginal devices, pelvic ﬂoor muscle exercises,
biofeedback, and functional electrical stimulation. In an
assessment of 13 systematic reviews on conservative treat-
ment of SUI, Latthe et al. concluded that pelvic ﬂoor muscle
training (PFMT) was better than no treatment [6]. Nine-to-
twelve-month success rates following PFMT with or without
biofeedback and/or health education programs range from
52.6%to74.8%[7–9].Long-termdurabilityinthesepatients
is likely a function of life-long exercise.
As there is no Food and Drug Administration (FDA)
approved medical treatment for SUI, there is a resultant void
in terms of invasiveness between conservative therapy and
surgical intervention. Urethral bulking agents have shown
beneﬁt, however, are indicated for the treatment of SUI due
to intrinsic sphincter deﬁciency (ISD), and are not univer-
sally administered in an oﬃce setting [10]. Renessa oﬀers an
oﬃce-based treatment for SUI in the absence of ISD through
radiofrequency energy (RF) delivered transurethrally under
local anesthesia.
2. Pathogenesis of SUI
ThepathogenesisofSUIisthoughttobetheresultofurethral
hypermobility secondary to a weakening or disruption of
the pelvic ﬂoor musculature and/or pubourethral ligament,
with a subsequent loss of pressure transmission from the
bladder to the urethra upon provocation [11, 12]. As most
women, independent of continence status, exhibit a measure
ofhypermobility,Blaivasetal.contendthatSUIisdependent2 Obstetrics and Gynecology International
upon the concomitant presence of vesical neck funneling
[13]. Ultrasound conﬁrmation of funneling in 111 patients,
as reported by Huang and Yang, was associated with a lower
maximal urethral closure pressure (MUCP), a smaller area
under the urethral pressure proﬁle curve, a lower Valsalva
leak point pressure (VLPP), and a larger volume of leakage
on pad test [14].
3. TransurethralRadiofrequency
Mechanismof Action
TransurethralRFtreatmentofthebladderneckandproximal
urethra is thought to reduce funneling through the denatu-
ration of submucosal collagen, with a resultant reduction in
tissue compliance. Similar technology has proven eﬀective in
thetreatmentofpatientswithgastroesophagealreﬂuxdisease
andfecalincontinence[15,16].Inapreclinicalporcinestudy
employing transurethral RF, Valsalva leak point pressure was
higher in the treatment group receiving 24 foci of RF energy
at 65◦C as compared to controls at 8 weeks (P = 0.06) [17].
4. Safety of Transurethral Radiofrequency
Transurethral RF collagen denaturation diﬀers from RF
ablation in that subnecrotic temperatures are employed,
resulting in collagen remodeling as opposed to necrosis [17].
Additionally, treated foci are microscopic, avoiding gross
tissue destruction. In the aforementioned animal study by
Edelstein, none of the 30 treated animals demonstrated
obstruction or stricture within the proximal urethra or
bladder neck. Histopathology after sacriﬁce revealed, most
commonly, focal chronic inﬂammation within the sub-
mucosa 1-2mm beneath the epithelium, with evidence
of ﬁbroplasia and vascular proliferation [17]( Figure 1).
Created are localized regions of denatured collagen at each
focus, approximately 200µ in diameter [23].
5.The Renessa Device
Renessa is an FDA-approved device which includes an
RF generator, a sterile single-use 21F transurethral probe,
foot pedal, probe interface cable, and standard AC power
cord (Figure 2). Low-power RF energy is delivered through
four partially insulated 23-gauge nickel-titanium needle
electrodes deployed from the probe shaft into the submucosa
of the bladder neck and proximal urethra (Figure 3). Tissue
temperatures are measured automatically. Impedance is also
reported prior to energy delivery to ensure appropriate
contact between electrodes and tissue. Irrigation of the
mucosa with sterile water occurs transurethrally throughout
the duration of the procedure to prevent overheating of the
mucosa and submucosa. Energy is delivered to a total of
thirty-six sites circumferentially.
6. ProcedureDescription
The radiofrequency probe is inserted until the tip is within
the bladder lumen. The balloon is then insuﬄated with
2 months (porcine)
Figure 1: Porcine bladder neck posttreatment with Renessa. histo-
logic image (hematoxylin and eosin) of porcine bladder outlet at
8 weeks following radiofrequency collagen remodeling. Denatured
collagen is surrounded by focal chronic inﬂammatory cells.
Figure 2: Renessa equipment.
10cc of water. To treat the bladder neck, the electrodes
are deployed ﬁrst, and gentle traction along the previ-
ously determined urethral axis is applied (approximately
1/2 pound of force with the operator’s index and middle
ﬁngers). The screen will display impedance upon initial
pedal pressure. If all electrodes read less than 300ohms,
the pedal is pressed again to begin radiofrequency delivery.
During treatment, the four electrodes traverse the mucosaObstetrics and Gynecology International 3
Table 1: Summary of Renessa clinical studies.
Study (year) Design Patients
(number)
Mean age
(range)
Follow-up
(months) Measures Outcomes Adverse events (%
incidence)
Sotomayor
and Bernal
(2005) [18]
Pilot clinical trial
with sequential
enrollment into 1 of
4 groups based on
number of
submucosal foci.
Group 1–24
Group 2–36
Group 3–48
Group 4–60
41 47.6
(34–81) 12 I-QOL
IEF
I-QOL—incidence of >10 point
score improvement.
Group 1: 63%
Group 2: 44%
Group 3: 70%
Group 4: 67%
Mean scores showed signiﬁcant
improvement for Groups 2–4.
IEF—incidence of ≥50%
reduction.
Group 1: 63%
Group 2: 67%
Group 3: 70%
Group 4: 89%
Urgency (22)
Dysuria (8)
Appell et al.
(2006) [19]
Randomized
sham-controlled
trial.
173
(110
Treated)
(63
Sham)
50
(22–76) 12
I-QOL
LPP (cm
H2O)
I-QOL—incidence of ≥10 point
score improvement.
Treated: 48%
Sham: 44% (P = 0.7)
LPP—mean ± SD
Treated: 13.2 ± 39.2
Sham: −2.0 ± 33.8 (P = 0.02)
AE (Rx, Sham
incidence)
Wet OAB (10, 9.5)
Dysuria (9.1, 1.6)
Dry OAB (7.3, 3.2)
UTI (4.5, 4.8)
Asymptomatic DO
(1.8, 6.3)
Retention (0.9, 0)
Hematuria (0.9, 0)
Hesitancy (0, 1.6)
Appell et al.
(2007) [20]
Retrospective
followup of
12-month RCT
21
(Treated)
52.2
(39.0–
65.4)
36 I-QOL
IEF
I-QOL—mean improvement:
12.7 points
IEF—incidence of ≥50%
reduction: 56%
No new AE’s
Elser et al.
(2009) [21]
Prospective
single-arm study
136
(ITT)
47.0
(26.0–
87.0)
12
I-QOL
IEF
UDI-6
PGI-I
PWT
I-QOL—incidence of ≥10 point
score improvement: 50.3%
Mean scores showed signiﬁcant
improvement (P<0.0001)
IEF—incidence of ≥50%
reduction: 50%
UDI-6—mean scores showed
signiﬁcant improvement
(P<0.0001)
PGI-I—improvement: 49.6%
(“very much” 14.4%, “much”
14.4%, “a little” 20.8%)
PWT—≥50% reduction: 69%
(45% < 1gram)
Dysuria (5.2)
Retention (4.4)
Pain (2.9)
UTI (2.9)
Increased leakage
(0.7)
Elser et al.
(2010) [22]
Prospective
single-arm study 136 (ITT)
47.0
(26.0–
87.0)
18
I-QOL
IEF
UDI-6
PGI-I
I-QOL—incidence of ≥10 point
score improvement: 47.8%
Mean scores showed signiﬁcant
improvement (P<0.0001)
IEF—incidence of ≥50%
reduction: 46.7%
UDI-6—mean scores showed
signiﬁcant improvement
(P<0.0001)
PGI-I—improvement: 50.4%
(“very much” 9.6%, “much”
15.2%, “a little” 25.6%)
No new AE’s
I-QOL: Incontinence quality of life instrument, IEF: incontinence episode frequency, LPP: leak point pressure, SD: standard deviation, Rx: treatedg r o u p ,A E :
adverse event, OAB: overactive bladder, UTI: urinary tract infection, DO: detrusor overactivity, RCT: randomized controlled trial, UDI-6: urogenital distress
inventory, PGI-I: patient global impression of improvement, PWT: pad weight test, and ITT: intent to treat.4 Obstetrics and Gynecology International
Figure 3: Probe with electrodes deployed delivering treatment.
Figure 4: Probe with markings.
and rest within the submucosa. Energy is delivered for
a 60-second cycle while sterile room temperature water
simultaneously irrigates the mucosa to prevent thermal
injury. The submucosa immediately surrounding the four
tips is heated and maintained at 65 degrees Celsius for a
minimum of 30 seconds. The electrodes are withdrawn, and
the probe shaft is repositioned after the ﬁrst treatment cycle,
ﬁrst 30 degrees to the right, and then 30 degrees to the left of
midline for cycles 2 and 3, respectively. Markings to guide
such rotation are in the form of longitudinal lines on the
probe shaft (Figure 4). The bladder neck receives a total of
12 discrete foci of denaturation.
To treat the proximal urethra, the same steps are carried
out; however, traction is placed on the probe prior to
deployment of the electrodes. Three cycles of energy are
delivered to the proximal urethra followed by another 3
cycles just distal to the initial site, achieved with a slightly
greater degree of traction. Thus, the proximal urethra
receives a total of 24foci of denaturation.
7. ClinicalRecommendations for Ofﬁce-Based
LowerUrinaryTract Anesthesia
The safe and eﬀective administration of topical and local
anesthesia must be fully considered, as it is essential for the
successful completion of Renessa in the oﬃce. Wells and
Lenihan reported on the feasibility of in-oﬃce anesthesia
in patients undergoing transurethral radiofrequency treat-
ment, employing preprocedure diazepam with a bilateral
periurethral block using a total of 10cc of 2% lidocaine [24].
Thirty-three women completed a visual analog scale (0 =
no pain, 10 = terrible pain) immediately prior to discharge.
Overall, 42% of patients rated their pain as 0, with a mean
pain score of 1.4 ± 1.8. The following is a summary of the
anesthetic regimen we currently employ.
7.1. Preprocedure Oral Regimen. The patient is instructed
to take an anxiolytic such as diazepam 5–10mg and a
nonsteroidal such as ibuprofen 800mg about 30–60 minutes
before the procedure.
7.2. Periurethral and Bladder Neck Topical Anesthesia. The
introitus is prepared with povidone iodine. A 6-inch catheter
is placed, and the bladder is drained. A negative urine dip
is conﬁrmed. Five cc of 2% xylocaine jelly is then infused
into the catheter as it is withdrawn. EMLA cream is placed
on a cotton swab and inserted transurethrally to rest at the
bladder neck. The resting urethral angle with swab in place is
determined by a goniometer to direct the orientation of the
Renessa probe during treatment.
A small aliquot of EMLA cream is also applied adjacent
to the urethral meatus at 3 and 9 o’clock in preparation for
injectionoflocalanesthesiaatthesesites.Experiencewiththe
safety and eﬃcacy of EMLA on the labia has been previously
demonstrated [25].
7.3. Periurethral and Bladder Neck Injection Anesthesia. After
10 minutes, a periurethral block is performed with a total
of 10cc of 1% xylocaine using a 22 gauge, 1 1/4” needle
introduced at the previously anesthetized 3 and 9 o’clock
sites. The needle is buried to the hub (to ensure anesthesia
of the bladder neck) along the urethral axis as determined
by the cotton swab present within the urethra. It should
be noted that the proximal urethra and bladder neck are
well vascularized, circumscribed by a pampiniform plexus
of veins. It is therefore essential that prior to injecting
xylocaine, one aspirates the syringe to reduce the possibility
of intravascular injection. Anesthetic is infused at each site in
two aliquots −3cc at the bladder neck followed by 1/2cm
withdrawal, aspiration and reinjection of the remaining
2cc’s. If additional anesthesia is required during treatment,Obstetrics and Gynecology International 5
another 5cc of 1% xylocaine may be administered as above
on either side.
7.4. Intravesical Bladder Neck Anesthesia. Immediately after
periurethral and bladder neck injection, intravesical anes-
thesia of the bladder neck is carried out. The cotton swab
within the urethra is removed, and a red rubber catheter is
placed to drain any residual urine. The bladder is retrograde
ﬁlled with 30cc of 1% xylocaine. The patient then stands
or sits upright to ensure contact between the intravesical
xylocaine and bladder neck. After 10 minutes, the bladder
is drained completely, ﬁlled with 30cc of sterile water at
room temperature (to cool tissue during treatment), and
the catheter removed. Complete evacuation of intravesical
anesthesia is suggested, as xylocaine absorption may be sig-
niﬁcantly increased in highly vascularized traumatized areas
such as the bladder neck and proximal urethra following
treatment with Renessa.
7.5. Postprocedure Oral Regimen. Patients are given a pre-
scription for phenazopyridine 200mg three times a day for
three days to provide lower urinary tract analgesia. The
administration of postprocedure antibiotics may be at the
discretion of the physician.
8.ClinicalData
A summary of prospective trials employing Renessa is pre-
sented in Table 1 [18–22]. Inclusion criteria common to all
studies were SUI and urethral hypermobility, with exclusion
of those with a history of previous anti-incontinence surgery
and those with primary urge-associated leakage in the
presence of mixed incontinence. In the Appell and Elser
trials, patients with a LPP of <60cm H2Oo nu r o d y n a m i c s
were not eligible for participation [19, 21].
Regarding 12 to 18 month eﬃcacy, patients treated with
low-energy RF to 36 submucosal foci exhibited a ≥10 point
score reduction in I-QOL ranging from 44% to 50.3%, and
a ≥50% reduction in IEF ranging from 46.7% to 67%.
An I-QOL score improvement of ≥10 points has been
shown to correlate with patient perception of improvement
as being “much better,” a ≥25% reduction in IEF, and a
≥25% reduction in stress pad weight [26]. Although no
statistically signiﬁcant diﬀerence was observed by Lenihan
et al. between treatment and sham groups regarding a ≥10
point improvement in I-QOL, a subanalysis of patients
deemed to have moderate-to-severe SUI determined that
74% of those receiving treatment versus 50% of those
receiving sham achieved such improvement (P = 0.03) [27].
Additionally, outcomes in this population were independent
of menopausal status.
Patients treated with transurethral RF collagen denatu-
ration experienced rare long-term sequelae. No serious AE’s
were reported in any of the aforementioned clinical trials,
and no diﬀerence was seen in the incidence of AE’s between
treatment and sham groups.
9. Discussion
Renessa represents an oﬃce intervention for SUI that is safe
and is without signiﬁcant AE’s or known long-term negative
eﬀects. Safety has been conﬁrmed in animal studies with no
evidence of posttreatment urethral obstruction or stricture
formation. The putative mechanism of decreased funneling
may be supported by both animal and human data in which
LPP was found to improve following RF treatment [17, 19].
Eﬃcacyoftransurethralcollagendenaturationappearsto
be within range of that of PFMT. Alewijnse et al. reported
1-year success following PFMT (with randomization of 129
patientstoPFMTaloneversusPFMTplusoneofthreehealth
education programs), citing a ≥50% improvement in IEF in
74.8% (64.4% by intent to treat) of patients overall [7].
In terms of actual number of leaks, Elser et al. reported
a reduction in median weekly IEF from a 15.0 (1.0 − 245.0)
to 7.5 (0.0 − 140.0) at 12 months (P = 0.0026) [21]. This
is in line with data from the Alewijnse trial in which was
reported a reduction in mean weekly IEF from 22.9 ± 24.1
to 7.8±12.2a t1 2m o n t h s( P<0.001). In a large RCT of 530
patients randomized to individual or group PFMT, Janssen
et al. reported similar data at 9 months, with a reduction in
mean weekly IEF from 16.3 ± 15.8t o8 .6 ± 15.5a n df r o m
14.4±15.3t o6.1±10.5fortheindividualandgrouppatients,
respectively, [8].
Eighteen-month data following Renessa shows improve-
ments at 12 months to be durable [22]. This may be
an advantage over PFMT, as durability following pelvic
ﬂoor muscle rehabilitation may be wholly dependent upon
continued therapy.
We chose not to compare our data to bulking agents, as
Renessa is indicated for SUI and not ISD. Additionally, as
transurethral RF treatment is in-oﬃce, we did not compare
such therapy to surgical anti-incontinence data.
10. Conclusion
Radiofrequency collagen denaturation is a safe, nonsurgical,
and in-oﬃce procedure for the treatment of female SUI,
providing an improvement in quality of life. Such therapy
may represent an alternative to PFMT or for those who have
failed such treatment.
11. Coding
The current procedural terminology code (CPT) for the
Renessa procedure is 53860.
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